A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2011
The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell Transplant (ASCT), had superior efficacy compared to rituximab in the same population.
Epistemonikos ID: 469ba242498fe7bdad948ff0c6d394e52f1e0d15
First added on: Jan 21, 2022